1.Humanizing NOD/SCID/IL-2Rγnull (NSG) mice using busulfan and retro-orbital injection of umbilical cord blood-derived CD34+ cells.
Young Kyung KANG ; Yunmi KO ; Aery CHOI ; Hyeong Jwa CHOI ; Jin Hee SEO ; Minyoung LEE ; Jun Ah LEE
Blood Research 2016;51(1):31-36
BACKGROUND: Humanized mouse models are still under development, and various protocols exist to improve human cell engraftment and function. METHODS: Fourteen NOD/SCID/IL-2Rγnull (NSG) mice (4‒5 wk old) were conditioned with busulfan and injected with human umbilical cord blood (hUCB)-derived CD34+ hematopoietic stem cells (HSC) via retro-orbital sinuses. The bone marrow (BM), spleen, and peripheral blood (PB) were analyzed 8 and 12 weeks after HSC transplantation. RESULTS: Most of the NSG mice tolerated the regimen well. The percentage of hCD45+ and CD19+ cells rose significantly in a time-dependent manner. The median percentage of hCD45+cells in the BM was 55.5% at week 8, and 67.2% at week 12. The median percentage of hCD45+ cells in the spleen at weeks 8 and 12 was 42% and 51%, respectively. The median percentage of hCD19+ cells in BM at weeks 8 and 12 was 21.5% and 39%, respectively (P=0.04). Similarly, the median percentage of hCD19+ cells in the spleen at weeks 8 and 12 was 10% and 24%, respectively (P=0.04). The percentage of hCD19+ B cells in PB was 23% at week 12. At week 8, hCD3+ T cells were barely detectable, while hCD7+ was detected in the BM and spleen. The percentage of hCD3+ T cells was 2‒3% at week 12 in the BM, spleen, and PB of humanized NSG mice. CONCLUSION: We adopted a simplified protocol for establishing humanized NSG mice. We observed a higher engraftment rate of human CD45+ cells than earlier studies without any significant toxicity. And human CD45+ cell engraftment at week 8 was comparable to that of week 12.
Animals
;
B-Lymphocytes
;
Bone Marrow
;
Busulfan*
;
Fetal Blood
;
Hematopoietic Stem Cells
;
Humans*
;
Mice*
;
Spleen
;
T-Lymphocytes
;
Umbilical Cord*
2.Metformin displays in vitro and in vivo antitumor effect against osteosarcoma.
Yunmi KO ; Aery CHOI ; Minyoung LEE ; Jun Ah LEE
Korean Journal of Pediatrics 2016;59(9):374-380
PURPOSE: Patients with unresectable, relapsed, or refractory osteosarcoma need a novel therapeutic agent. Metformin is a biguanide derivative used in the treatment of type II diabetes, and is recently gaining attention in cancer research. METHODS: We evaluated the effect of metformin against human osteosarcoma. Four osteosarcoma cell lines (KHOS/NP, HOS, MG-63, U-2 OS) were treated with metformin and cell proliferation was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell cycle progression and apoptosis were evaluated using flow cytometric analysis, and migration and wound healing assay were performed. Fourteen female Balb/c-nude mice received KHOS/NP cell grafts in their thigh, and were allowed access to metformin containing water (2 mg/mL) ad libitum. Tumor volume was measured every 3–4 days for a period of 4 weeks. RESULTS: Metformin had a significant antiproliferative effect on human osteosarcoma cells. In particular, metformin inhibited the proliferation and migration of KHOS/NP cells by activation of AMP-activated protein kinase and consequent inhibition of the mammalian target of rapamycin pathway. It also inhibited the proliferation of cisplatin-resistant KHOS/NP clone cells. Analysis of KHOS/NP xenograft Balb/c-nude models indicated that metformin displayed potent in vivo antitumor effects. CONCLUSION: Further studies are necessary to explore metformin's therapeutic potential and the possibilities for its use as an adjuvant agent for osteosarcoma.
AMP-Activated Protein Kinases
;
Animals
;
Apoptosis
;
Cell Cycle
;
Cell Line
;
Cell Proliferation
;
Clone Cells
;
Female
;
Heterografts
;
Humans
;
In Vitro Techniques*
;
Metformin*
;
Mice
;
Osteosarcoma*
;
Sirolimus
;
Thigh
;
Transplants
;
Tumor Burden
;
Water
;
Wound Healing
3.The impact of an educational intervention on parents' decisions to vaccinate their <60-month-old children against influenza.
Aery CHOI ; Dong Ho KIM ; Yun Kyung KIM ; Byung Wook EUN ; Dae Sun JO
Korean Journal of Pediatrics 2017;60(8):254-260
PURPOSE: Seasonal influenza can be prevented by vaccination. Disease prevention in children aged <60 months is of particular importance because of the associated familial and societal burden. Considering that caretakers make the decision to vaccinate their children, the identification of drivers and barriers to vaccination is essential to increase influenza vaccination coverage. METHODS: A total of 639 parents participated in the pre- and posteducational survey and 450 parents participated in the study via telephone interviews. The participating parents were asked to rank their agreement with each statement of the survey questionnaire on a scale from 1 (strongly disagree) to 5 (strongly agree), and the scores between pre- and postintervention were compared. RESULTS: Before the educational intervention, 105 out of 639 participants reported not to agree to vaccinate their children against influenza. After the intervention, 46 out of the 105 parents changed their opinions about childhood vaccination. The physicians' recommendation received the highest agreement score and was the most important driver to vaccination, whereas the cost of vaccination was the strongest factor for not vaccinating children. In general, the participants significantly changed the agreement scores between pre- and postintervention. However, the unfavorable opinions about vaccination and the convenience of receiving the influenza vaccine did not change significantly. CONCLUSION: The results of this study indicate that a specific educational intervention involving caregivers is very effective in increasing the influenza vaccination coverage of children aged less than 60 months.
Caregivers
;
Child*
;
Humans
;
Influenza Vaccines
;
Influenza, Human*
;
Interviews as Topic
;
Parents
;
Seasons
;
Vaccination
4.Severe Hepatic Sinusoidal Obstruction Syndrome in a Child Receiving Vincristine, Actinomycin-D, and Cyclophosphamide for Rhabdomyosarcoma: Successful Treatment with Defibrotide.
Aery CHOI ; Young Kyung KANG ; Sewon LIM ; Dong Ho KIM ; Jung Sub LIM ; Jun Ah LEE
Cancer Research and Treatment 2016;48(4):1443-1447
Hepatic sinusoidal obstruction syndrome (SOS) is a life-threatening syndrome that generally occurs as a complication after hematopoietic stem cell transplantation or, less commonly, after conventional chemotherapy. Regarding SOS in rhabdomyosarcoma patients who received conventional chemotherapy, the doses of chemotherapeutic agents are associated with the development of SOS. Several cases of SOS in rhabdomyosarcoma patients after receiving chemotherapy with escalated doses of cyclophosphamide have been reported. Here, we report on a 9-year-old female with rhabdomyosarcoma who developed severe SOS after receiving chemotherapy consisting of vincristine, actinomycin-D, and a moderate dose of cyclophosphamide. She was treated successfully with defibrotide without sequelae to the liver.
Child*
;
Cyclophosphamide*
;
Drug Therapy
;
Female
;
Hematopoietic Stem Cell Transplantation
;
Hepatic Veno-Occlusive Disease*
;
Humans
;
Liver
;
Rhabdomyosarcoma*
;
Vincristine*
5.Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density.
Se Won LIM ; Ju Hyun AHN ; Aery CHOI ; Wan Hyeong CHO ; Jun Ah LEE ; Dong Ho KIM ; Ju Hee SEO ; Jung Sub LIM
Annals of Pediatric Endocrinology & Metabolism 2016;21(1):21-25
PURPOSE: Most surviving pediatric osteosarcoma patients experience osteoporosis, bone pain, and pathologic fracture during and after therapy. The aim of this study was to evaluate the efficacy and side effects of pamidronate therapy in these patients. METHODS: Nine osteosarcoma patients (12.8±1.6 years of age; 5 boys and 4 girls) who had a history of nontraumatic fracture or severe pain after completing chemotherapy were included. Intravenous pamidronate (1.5 mg/kg) was given every 6 weeks for 4 to 6 cycles. Bone mineral density (BMD) of the lumbar spine was measured by dual-energy x-ray absorptiometry. Clinical outcomes including acute side effects were also evaluated. RESULTS: After pamidronate treatments, all patients experienced decreased pain. Seven of 9 patients could walk without a crutch. The BMD of lumbar spine was increased by 0.108±0.062 mg/cm2 after 8.4±1.0 months (n=8, P=0.017) and the mean z-score improved from -2.14±0.94 to -1.76±0.95 (P=0.161). Six patients (67%) had an acute-phase reaction, and 2 patients had symptomatic hypocalcemia. CONCLUSION: Pamidronate appears to be safe and effective for the treatment of osteosarcoma in children with low BMD and bone pain.
Absorptiometry, Photon
;
Acute-Phase Reaction
;
Bone Density*
;
Child
;
Drug Therapy
;
Fractures, Spontaneous
;
Humans
;
Hypocalcemia
;
Osteoporosis
;
Osteosarcoma*
;
Spine